Who owns INOVIO PHARMACEUTICALS, INC. (INO)? Elite investor 13F holders
2 tracked elite investors reported holding INOVIO PHARMACEUTICALS, INC as of 2026-06-30, including D.E. Shaw, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| D.E. Shaw | INOVIO PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 1486822.00 USD | 1351656.000000 | Shares | reduce | Original filing |
| Renaissance Technologies LLC | INOVIO PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 397473.00 USD | 361339.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.